Requesting Institution/ OrganisationApplicant Name Purpose Material RequestedFundingDecision Request DateDecision DatePublication DOIOther outcomes
University of Oxford
Theresa Lambe & Sarah Gilbert
Vaccine DevelopmentSera - 5mlInternal fundingApproved29/02/202024/03/2020
Liverpool School of Tropical Medicine
Emily AdamsAssay Development
Serum from 10 convalescent patients 5ml
Sumathi Sivapalasingam
Production of therapeutic antibodies from B cells
50ml of whole bloodInternally fundedApproved10/03/202024/03/2020
Biogene ResearchNelson Nazareth
Testing against CDC/PHE primer/probe set
40 swabsNo fundingReapply when funded11/03/202024/03/2020
University of EdinburghFrancisca Mutapi
Develop an elisa-based immunoassay for detecting Covid-19 antibodies
100ul convalescent plasma/serum. 12.06.2020 1ml WO
We (NIHR Unit Tackling Infections to benefit Africa (TIBA) at the University of Edinburgh) are funded by the UK National Institutes of Health Research through the Global Health Research Fund. As part of this funding we were instructed to use some of the funding for research to respond to national of global health emergencies
PEPperPRINTVolker Stadler
Diagnostic COVID-19 peptides in collaboration with University of Edinburgh
Convalescent serum -1ml
PEPperPrint: internal funding UoE: NIHR
AstraZenecaMark Esser
Identify B cells that secrete neutralizing antibodies against the SARS-CoV-2 virus.
Convalescent serum – 5mlInternal fundingApproved17/03/202024/03/2020
Ministry of DefenceStevan Emmett
Partial validation of 3 commercially available lateral flow cassettes.
Day 1,3 and 9 plasma or serumGovernmentally funded
Approved for diagnostic evaluation platform
Brighton and Sussex Medical School
Florian Kern
Expansive peptide array to detect antibody responses spanning full proteome
10-20ul serum. Recovered patients. Clinical course must be known. ~ 100 samples.
Not yet fundedApprove if funded22/03/202013/04/2020
Health Protection Scotland
Antonio Ho
Validate a serological ELISA assay for immunological response curve
Serum samples at least 500ul. Helpful if it's pared as acute and convalescent. N=50.
Governmentally fundedApproved28/03/202013/04/2020
Quotient BDReginald Clayton
Diagnostic serology assay for use in hospitals and blood testing insitutions.
5ml plasma or serum samples. Preferably dozens
Quotient R&D budget.Approved28/03/202013/04/2020
University of OxfordRoman Fischer
Determine the plasma proteome in COVID-19 patients
Plasma - 50µl from 400 patientsInternal fundingApproved02/04/202013/04/2020
Imperial College LondonKatrina Pollock
Understanding the pathogenesis through standard lab techniques like ELISAs
Serum and Plasma. 1ml vial of urine and oral swabs if available. Male patients moderate and severe
MRC/UKRI rolling funding call
University of EdinburghChris HaleyGWAS of DNA methylationAccess to DNA samplesFunding pendingApproved06/04/202013/04/2020
University of EdinburghAlex von Kriegsheim
Quantify lipids and metabolites using mass spectrometry lipidomics/ Steroid analyses
Plasma - 100µl from 600 patients - 12.06.2020 request changed to 500ul for steroid analyes, 60 severe, 60 mild, 80 unifected (unavailable)
Funding pendingApproved06/04/202013/04/2020
University of LiverpoolSimon Abrams
Validate the multivariable prognostic model established in Chinese cohorts. Compare prognostic variable with circulating histones.
Plasma - 500µl from 200 patientsInternal fundingApproved06/04/202013/04/2020
University of LiverpoolJames Stewart
Development and selection of antigens for diagnostics and vaccine candidates. Establish ELISAs using antigen proteins
2ml convalescent serum. 6+ patients.
Core BBSRC funds. University of Kent funds.
Approved for diagnostic evaluation platform
University of LiverpoolQingging Zhang
Super-neutralising antibodies pull-down using Spike protein conjugated beads
Serum – 10ml from 20 patientsNHS R&D grantApproved08/04/202013/04/2020
University of GlasgowJohn McLauchlan
Host genotyping for IFNL4 for COVID-19 patients.
1-2ml serum of up to 400 patients.Core funded.Declined08/04/202013/04/2020
University of EdinburghDamian Mole
Stratification of COVID-19 patients using 2 established metabolic pathway panels.
N=500 X 100uL of plasma or serum
MRC fellowship and existing industry collaborations
British HIV Association Group
Sophie Kelly
Investigate infection rate and disease course of COVID-19 in HIV patients.
Periodic reports of HIV positive patients. Access to immunology, serology and PCR results. Every 1-3 months. Samples: Serum/plasma 500ul from as many HIV-positive patients as possible.
Internally fundedApproved13/04/202028/04/202010.1093/cid/ciaa1605
Imperial College LondonRoya E Haghihat-Khah
RNA seq to investigate differential gene expression between patient groups (eg age, sex, hypertension treatment and recovery)
RNA from Oracol or viral throat swabs. RNA or materials from 300 patietns.
UKRI funding in processApproved14/04/202028/04/2020
University College London
Benny Chain
Machine learning to identify T-cell receptor signature that predicts clinical outcomes.
Blood RNA (600ng extracted from tempus tubes) Day 1,3,9 and 28. 300 longitudinal patients.
UKRI funding application depending on sample access
University of OxfordSusie Dunachie
Phenotypic and functional T-cell responses to COVID-19 vaccine targets and identify metabolism differences in Type 2 diabetes patients.
4 million PBMCs from 50 COVID-19 patients with and without Type 2 diabetes at Day 1 and Day 28 (where available). Linked patient metadata including age, gender, disease severity, supportive care received, trial treatments and outcome. Matched for age, gender and disease severity at Day 1.
Salary and lab running costs covered by existing grants. Applying for Diabetes UK COVID-19 Rapid Response for further funding.
Approved20/04/202028/04/2020PITCH Study protocol
University of EdinburghPaul Brennan
Infrared spectroscopy-based test for COVID-19 risk stratification and immunity
50ul serum from day 1, 9 and 28 of 200 patients. If not possible, Day 1 and 28 possible.
UKRI, CSO and others for validation phase. Algorithm training can start without funding.
University of Liverpool and Liverppol University Hospitals NHS Foundation Trust
Douglas B Kell (PI) Andrew S Davison
Untargeted metabolomics of serum samples during COVID-19. Longitudinal sampling to asses relationships between metabolites and infection, disease progression, severity and outcome. Samples will be analysed using high-resolution mass spectrometry.
Surplus serum and anonymised metadata (age, sex, disease status and other clinical information) collected in Liverpool Clinical Laboratories. Each sample requires a minimum volume of 150ul.
Funding pendingApproved21/04/202028/04/2020
University of EdinburghYanick Crow
Measuring INF-alpha in COVID-19 patients using an ultrasensitive digital ELISA assay
Serum or plasma (100ul)
Funding in place for 100 samples. Funding pending for 1000+ samples.
University of LiverpoolJonathan Cattrall
Investigating neurological disease in COVID-19 through clinical features, risk factors and analysis of CSF and sera to understand disease mechanisms.
Data - analysis of patient data with features suggestive of neurological disease. Determine risk factors for neurological disease. If protocols and ethics allow, detailed questionnaire to be sent to research sites and contact patients for more info re outcome. Samples- CSF (2ml - min of 100ul doable) and serum (2ml). Unsure how many samples may be available.
Funding from NIHR HPRU in EZI
McGill Quebec, CanadaBrent Richards
Elucidate host genetic determinants and develop predictive models for COVID-19 severity by using phenotypic data.
All phenotypic data (biochemical, hematological, immunological data), host genotype data, RNA seq data (D1,3,9 and 28). Viral sequencing data for host genetics and viral sequence.
Quebec provincial government and Fonds de recherche du Quebec - Sante.
Approve for collaboration
University of LeicesterKamlesh Khunti
Identify vulnerable groups at risk of disease. DHSC letter of support.
Clinical data collected on admission, daily and outcome forms. Differences in outcomes based on ethnicity, co-morbidities, obesity and socio-economic status.
NIHR ARC East MidlandsApproved30/04/202030/04/2020
University of EdinburghGwo-Tzer Ho
Investigate DAMPs assays as prognostic marker. Drug treatments that block the action of DAMPs. Clarify role of gut ACE2 expression and transmissibility. Understanding gut microbiome and whether clinial outcome can be predicted from GI microbiome data.
Serum and plasma (5mls) - 200 patients (100 ICU vs 100 non-ICU). Stools (5-10ml) 1000 patients with associated clinical data (cluster 3 - with GI symptoms vs non-GI symptoms). Clinical data - 1000 patients stratified by disease severity and clinical phenotype - with or without diarrhea.
Helmsley Trust, ERC, Scot Government RESAS, BBSCRC, and funds form Scottish Senior Fellowship.
University of Liverpool
Lance Turtle Julian Hiscox
Determining the ability of culturing SARS-CoV-2 virus using respiratory tract swabs.
20-50 respiratory tract swabs from patients with severe COVID-19 and mild/moderate disease respectively.
Internally fundedApproved01/05/202004/05/2020
Personal CapacityEduardo Henrique
Highlighting severity of COVID-19 to better inform Brazilian population
Clinical data - demographics, details regarding presentation, admission and clinical outcomes.
Imperial College London
Zoltan Takats James Kinross Lauren Ford *In combination with Request 47 Dumas
Ambient mass spectrometry techniques for metabolite biomarkers of COVID-19 status and host immune response and a protease assay for a rapid, point-of-care test.
Combined nose and throat swabs, otherwise a throat swab or nasopharyngeal swab alone. As many as possible.
Imperial Biomedical Research Centre.
Imperial College London
Marc-Emmanuel Dumas Julian Griffin Zoltan Takats Peter Openshaw *In combination with Request 43 Takats
Metabolomic profiling of COVID-19 to improve mechanistic understanding, provide insights into secondary biological effects and further develop prognostic markers.
All 650 patients at 4 timepoints - 2600 samples. Plasma (or serum) 375ul per sample. Urine 275ul per sample. Stool 500mg per sample. Swab metabolomics - Prof Takats application (Request 43)
Imperial Biomedical Research Centre.
University of Liverpool University of Sheffield University of Oxford
Lance Turtle Paul Klenerman Thusan DeSilva Susie Dunachie Ellie Barnes Alex Mentzer
Phenotypic and functional T-cell response to SARS-CoV-2 including vaccine targets. Greater capacity and samples than original ISARIC-4C aims of characterising the immune response.
30-40 million PBMCs from all donors sampled. Final sample sizes to be determined as part of the ISARIC-4C follow up WP9.
Internally funded by University of Liverpool and University of Oxford.
Approved04/05/202004/05/2020PITCH Study protocol
University of OxfordAndrew Soltan
AI algorithms to rapidly identify COVID-19 illness at the front-door of hospitals.
Essential data: Admission blood tests - FBC, U&Es, LFTs, CRP, Clotting function, Microbiology, SARS-CoV-2 results, influenza results (where tested) admission observations (if available). Desirable: Single set of pre-morbid blood tests values for the same parameters.
Imperial College London
Roberta Forlano Mark Thurz Pinelopi Manousou Benjamin Mullish
Risk factors of COVID-19 patients with non-alcoholic fatty liver disease
Clinical data - demographics, blood test results, details regarding presentation, admission and clinical outcomes.
Imperial Biomedical Research Centre.
MathworksPeter Maloney
Development of a multifactorial RSM tool to improve outcomes and triaging of patients
Raw data used to create survival from onset plot and Symptoms on presentation to hospital bar graph.
Internally fundedApproved05/05/202006/05/2020
London School of Hygiene and Tropical Medicine
Fiona Woo Katherine Atkins Stephane Hue
Phylogenetic modeling to evaluate the role of hospital-acquired infection in sustaining UK transmission
Request for CO-CIN data. For all patients with positive SARS-CoV-2 test and viral sequence from nasal/saliva swab sample. Data variables - employed as healthcare worker, DOB/age, outer postcode, onset data, admission date, readmission?, transfer from other facility? collection date for samples, outcome and date, full lenght viral genome seq for SARS-CoV-2
Internally fundedApproved06/05/202006/05/2020
ExplantlabDavid Langton
Investigating variations in the major histocompatibility complex and COVID-19
5-10ml EDTA - intubated/CPAP, <65yrs, no comorbidities. Total of 75 patients. Would require accompanying demographic data
Internally fundedResubmission07/05/202008/05/2020
Liverpool University Hospitals Foundation NHS trust and University of Liverpool
Sree Subramian
Link between Vit D deficiency and at risk groups for severe COVID-19 illness and death.
Plasma or serum (500ul). All patients fom Tier 1, or 500 approx. would require 0.5ml plasma or serum (they have 250 tier 0 patients of their own)
£20 000 funding in place for Vit D assays.
Approved for Tier 007/05/202008/05/2020
Liverpool School of Tropical Medicine
Ryan Robinson Andrea Collins
Investigate reationship between immunosuppressive treatments and mortality risk of COVID-19 patients.
Immunosuppressive therapy duration and type, demographics, requirement for HDU/ITU admission, mortality rate and duration of inpatient stay.
Internally fundedApproved07/05/202008/05/2020
Trisomy 21 Research Society
Andre Strydom Stephanie Sherman Mara Dierssen
Impact of COVID-19 on individuals with Down Syndrome.
Clinical data incl demographics, co-morbidities, medication,treatment, outcomes etc.
LuMind IDSC Foundation and other Down Syndrome organisations
University College London
Nikhil Sharma
Investigating differences in the gut microbiome and clinical course of COVID-19
Stool samples (<0.5g) - 1000 (different subsets) and clinical metadata
Funding pendingApproved12/05/202012/05/2020
University of SheffieldFelipe Soares
An intelligent system for the pre-triage of COVID-19 suspected patients based on simple blood exams and data science to benefit resource-poor settings in LMICs.
Clinical data: Demographics, onset and admission, vital signs at admission, co-morbidities, daily lab results, daily treatment, pathogen testing, treatment, outcome.
Funding pendingApproved14/05/202015/05/2020
Queen's University Belfast
Christina Branco
Inflammatory signals that can affect microvascular function such as endothelial activation, permeability or intercellular recruitment signals.
Plasma (500ul min); clotted serum (100ul min); blood in blood RNA tube (200ul min). At least 20 depending on variation between disease severity.
Access to samples required to secure funding.
University of MiamiManish Kuchakulla
AI tool to generate a neural network to improve diagnosis and predicting prognosis of disease.
Clincal data: demographics, symptoms, lab values and co-morbidities.
Part internally funded, part funded by philanthropy.
Loughborough UniversityLiam Heaney
The impact of the gut microbiome for the risk/severity of COVID-19, by investigating gut microbiota-derived metabolites using mass spectrometry-based assays.
Serum (250ul) maximum number available at visit 1. Clinical data - demographics, laboratory results, and outcome data.
Funding application dependent on sample approval.
University of OxfordEmily Thornton
Gut inflammation and the microbiome and adverse patient outcomes
Stool samples (>500mg) as early in disease matched with immunophenotyping data from ISARIC, clinical phenotype and routine lab data.
Internal funding, will apply for external funding with pilot data.
BG ResearchNelson Nazareth
Resubmission as per feedback - Direct RT-qPCR amplification and detection of SARS-CoV-2 from nasal swab eluates, saliva, etc. Working in Emily Adams in LSTM lab.
40 positive combined nose and throat swabs or alone. Preferably from same individual from day 1,3,9 as per protocol or 40 from day 1.
DASA accelerator COVID research program
CRN Yorkshire and Humber
Rebecca Byrne
The data is to better understand the relationship between ethnicity and both participation in COVID research as well understanding the impact on individuals from BAME communities.
Access to CRF data - specifically related to ethnicity and outcome measures
Internally fundedApproved19/05/202025/06/2020
Royal Wolverhampton NHS Trust
Srinivisan Venkatachalam
COVID Hyperinflammation study. Use of ISARIC-4C dataset for the Wolverhampton patients to support COVIDHI study.
Clinical characteristics of all COVID patients entered into ISARIC from The Royal Wolverhampton NHS Trust
Internally fundedApproved26/05/202022/07/2020
University of EdinburghAndrea Wilson
Data-driven now-casting & fore-casting of health-care resource requirements associated with COVID-19 in Edinburgh and South-East Scotland
CO-CIN data from Tiers 0. 1, 2 from Scotland and rest of UK.
Internally fundedApproved27/05/202003/06/2020
Nottingham Trent University
Graham Ball
Prediction of host response to the disease benefit using systems biology approaches
Omics data or biomarker panel data from patients and corresponsding clinical parameters, ethnicity and outcome data.
Internally funding
Duplication of planned work -will share data once available
University of LondonCamilla Benfield
PCR based identification of SNPS within a host immunity gene and associations between alleles and haplotypes.
PBMCs (cell pellets or DNA) from 250 sever COVID-19 patients and 250 mild cases (matched for age/gender). Patient data on ethnicity and co-morbidities also sought. Also combined nose and throat swab, or extracted DNA from these swabs.
Funding pending
Duplication of planned work -will share data once available
University of GlasgowMiguel Pineda
Influence of human glycosylation pathways in COVID-19 clinical outcome
RNA from infected tissues, throat swabs or nasal specimens, Samples from 2 patients groups: mild and severe disease outcomes (10-15 patients per group) Days 1,3,9 and 28. Associated clinical data
Funding for pilot study. Will apply for further funding with IDAMAC support.
University of York
Nathalie Signoret Dimitris Lagos
Patients from Yorkshire and Humber - identify correlates of natural immunity, disease development, and recovery. Blood biomarkers of COVID-19 patients with a mixed demographic origin.
Plasma (750ul - 1.5ml) from Tier 1 from adults. Up to 100 depending on availability.
Start with repurposed funding, applying for UKRI rapid response rolling call.
COPD Consortium/Imperial
Paul Cullinan Chloe Bloom Brian Lipworth Thomas Drake Annemarie Docherty
Does inhaled corticosteroid use have an impact on clinical outcomes in patients with COVID-19 disease and either asthma or other chronic respiratory disease; and examindation of UK ISARIC data?
All data from CRF v9.4, all admissions to date of data access; to include relevant measurements in plasma and other biosamples.
Internal fundingApproved09/06/202022/07/2020
Medway NHS Foundation Trust
Annette Woods
Determining whether medication taken by patients are protective or limits the prorgress of disease specific to Medway NHS Trust
Site specific data from patients - demographics and all data submitted so far.
Initial review do not need funding, further funding applications if succesful.
Non-academic teamRory Dunne
Aid diagnosis and prognostic evaluation by using cytokine profiles to distinguish between concurrent outbreaks of influenza and coronavirus
Demographics, outcomes, clinical data and cytokine data
Self-funded, will apply for further funding if succesful
West Hertfordshire Hospitals NHS Trust
Rama Vancheeswaran
Validation cohort for risk prediction study with longer term outcomes called PREDICT COVID.
Data from 5000 patients in population for external validation tool.
Internally fundedApproved11/06/202022/07/2020
University of Glasgow
Colin Berry Alex McConnachie John Cleland Antonia Ho
Characterise cardiac risk in COVID-19 to guide clinicians on risk stratification and therapy in high-risk groups.
Database accessInternally fundedApproved12/06/202022/07/2020
Queen's University Belfast
Ultan Power
Screen FDA-approved drugs for antiviral and anti-inflammatory activities in vitro - using viral strains for validation.
Access to 5 anonymised clinical samples (nasal/throat swabs or nasopharyngeal aspirates) from SARS-CoV-2 patients from different geographical locations. Access to 5 low passages (P4) SARS-CoV-2 strains.
UKRI/NIHR COVID-19 Rapid Response
MC DiagnosticsPeter MaguireCommercial - HLA typing
1ug DNA per patient, capacity for over 1000 - application through GenoMICC.
Internally fundedApproved16/06/202022/07/2020
Epsom & St Helier University NHS
Rachel Wake
Investigating Trust specific nosocomial transmission to assist triaging and cohorting to prevent viral exposure to susceptible patients.
Tier 0 data collected at Epsom & St Heliers
Internally fundedApproved16/06/202022/07/2020
University College London Hospital, NHS Foundation Trust
Kevin Fong
This is a high resolution, agent based mathematical model developed with the intention of delivering improved capability to model non-pharmaceutical interventions.
These data will be used to inform epidemiological modelling and refine model assumptions.
NHS EnglandApproved19/06/202018/12/2020
University of OxfordLuis Sota Mota
Test and compare the performance of different mortality prediction scores to support developing countries
Clinical dataInternally funded
Referred to international ISARIC team
Crick Institute
Andrew Bretherick, Markus Ralser, Kenneth Baillie
Investigate plasma proteome to inform clinical practice thourgh trajectories and associations, prognostic models of disease outcome and identify novel potential therapeutic targets
40ul EDTA plasma - serial samples n=300. Tier 0 data - genetic data and demographic and clinical information.
Francis Crick InstituteApproved22/06/202022/07/2020
Imperial College LondonAmna Malik
Nichola Cooper
T-cell sequencing to identify differences between 'good responders (non-severe) and 'bad responders' (severe) patients to improve treatment outcomes.
1ml of blood in blood RNA tube at day 1,3,9 and 28. Access to metadata - age, sex, disease status and other clinical information.
Internally funded
Duplicates planned analyses
NHS Greater Glasgow & Clyde
Michael Murphy
We will produce a point of care antibody/immunoassay, building upon our recognised track record of sensitivity equivalence to ELISA demonstrated in serum and time to result <10 mins. We will translate this novel approach for use with SARS-nCoV-19 markers (indicating ongoing infection) and antibodies (indicating past infection). Within four months we will deliver a fully operational prototype validated with clinical COVID-19 samples. Importantly, we have engaged both industrial and clinical collaborators to unlock immediate validation and mass manufacture in Scotland, UK.
15 x 1ml saliva samples from COVID-19 patients. Corresponding data if possible.
CSO grantApproved26/06/202022/07/2020
University of LeedsJim Robinson
Locus specific genotyping of the Fc Gamma locus
Genomic DNA or cell pellets. Minimum of 300ng DNA required. Associated ISARIC clinical data
MRC CICApproved01/07/202022/07/2020
Imperial College London
Ramya Sriskandarajah Sruthi Ramaraju
Dynamic profile of immunological markers which independently predict COVID-19 outcomes
Data from the whole cohort for serum serial levels (day 1,3,9 and 28) for list of biomarkers. Clinical characteristics of patients, demographics, co-morbidities.
Internally fundedDeclined02/07/202025/08/2020
London School of Hygiene and Tropical Medicine
Daniel Ward
Innate and adaptive responses to SARS-CoV-2 infection - T- and B-cell receptor characterisation through deep seq of T/B-Cell receptor VDJ sequences. Multinational dataset - to include samples from Portugal, Brazil, Kenya, and Indonesia
30ml x 20 patients of whole bood (with anticoagulant) at days 1,3,9 and 28. 500ul of sera from 100 patients with range of disease. Metadata
Internally funded
Declined, sample do not exist
University Hospitals North Midlands NHS Trust
Jenny Wright
Can quantitative (real-time) polymerase chain reaction (PCR) cycle threshold (Ct) values be used to predict poor outcomes for patients infected with SARS-CoV-2?
Compare Ct value from local laboratory database for each patient in local ISARIC-4C dataset
Internally fundedApproved13/07/202025/08/2020
Public Health ScotlandGeorgia Ladbury
Enhanced surveillance and research of COVID-19 through sharing data with I-MOVE-COVID-19 Consortium to allow Scotland to contribute to a European-level COVID dataset.
Full data collected on all patients on CO-CIN who were hospitalised in Scotland from admission to the current date, and ongoing.
Government funded
Data is already being provided
University of Sheffield Medical School
Endre Kiss-Toth
Profiling of myeloid cell sub-types, and investigating the dysregulation of their intracellular signalling networks, epigenetic changes and their functional consequences in health vs. disease to identify early markers predictive of the disease progression
24ml whole blood from participants at their local site (Sheffield Teaching Hospitals NHS FT)
University of EdinburghGiles Calder-Gerver
Scottish Government Advisory Group - risk of hospitalisation and age.
Age-stratified data for COVID-19 hospitalisations in the UK - national or regional.
Internally funded
Data is already being provided
ExplantlabDavid Langton
Investigating variations in the major histocompatibility complex and COVID-19
75 COVID 19 patients who required respiratory support, no significant comorbidities, less than 65 years of age. DNA patients aged 20-50
Mount Sinai Center for Transformative Disease Modeling
Kuan-lin Huang
Clinical and genetic factors associated with prognosis and response for better patient management and understanding of how some patients survive the disease.
Data only, including patient genetics (SNPs), clinical/demographics data, blood RNA-Seq data, blood immune response data, mucusal response data, and viral load measures.
Year 1: ISMMS seed fund to K.H. Year 2-5: NIH R01 grant (pending).
Duplicates planned analyses will share data when available
University of Liverpool
Anne McArdle with Ryan Thwaites
Chronic fatigue in COVID-19 survivors and role that pre-existing or newly developed cardiovascular and/or respiratory dysfunction plays and whether cytokine clusters can predict severity of fatigue
Anonymised metadata of participants including age, sex, race, and socio-economic status. Plasma samples (100ul) from up to 104 hospitalised patients for cytokine analysis using Luminex platform. These patients will be retrospectively recruited.Access to routine blood analysis if available.
UKRI funding pending. Pump-priming funds from University of Liverpool for pilot study.
Imperial College LondonCharis Pericleous
Autoantibodies associated with thrombosis and inflammatory vascular damage - prevalence, specificity, and persistence of the autoantibody response
120ul of plasma from 100 ICU/HDU and 100 non-ICU/HDU COVID-19 patients from Tier 2 @ day 9 of sampling. Work can be carried out with residual samples from PO. Demographics, co-morbidities, clinical presentation, laboratory measurements, treatment outcome.
Imperial College COVID-19 FUND
Royal Devon & Exeter NHS
Lizzie Goodwin
Access to full ISARIC-4C dataset for site to upload to CAPACITY database
Tier 0 data for Royal Devon & Exeter site
CAPACITY funding
Declined, study leads to engage
Quadram InstituteArjan Narbad
The stool samples will be used for the validation of a method we have developed to test SARS-Cov-2 in faecal material.
Stool samples from 10 COVID-19 patients. We need approximately 200 mg /patient.
Internally funded
Pending sample availability
University of Oxford
Tom Beneke with Peter Openshaw & Alfredo Castello Palomares
Role of non-infectious SARS-CoV-2 RNA fragments in blood coagulation
Paired serum samples from 52 ISARIC-4C recruits where viral RNA was detected by qPCR (Ct < 37) - 140ul of each sample. If available, 20 paired plasma samples sets from COVID-naive recruits (1ml plasma each).
UKRI funding in process - as soon as confirmation received of sample access.
Royal Free London NHS Foundation Trust
Thomson, Gabriella Captur
plan to enroll patients in an international registry known as CAPACITY-COVID (
complete dataset derived from the Case Report Forms for all patients enrolled at the Royal Free Hospital, London
Processing of the ISARIC data and collection of the CAPACITY-specific fields will be carried out by clinicians with established funding. There will be no additional funding for this work.
Declined, study leads to engage
Royal Devon & Exeter NHS
Leila Fearne
To look at COVID-19 trends specifically around cardiac complications/past medical history.
Anonymized data from ISARIC to share with the CAPACITY RedCap database.
No funding attached
Declined, study leads to engage
Barts Health NHS Trust
Viyaasan Mahalingasivam
Investigate the long-term effects of COVID-19 on people with CKD to be undertaken at London School of Hygiene and Tropical Medicine.
Summary of how many patients from the ISARIC COVID cohort with/without CKD died and how many survived to discharge, stratified by other baseline characteristics.
Applying to NIHRApproved30/07/202018/12/2020
Machine Learning and Biomarkers Group
Immo Weichert
Investigating predictors of COVID kidney - development of AKI, need for renal replacement therapy and long term renal impairment after becoming ill with SARS-CoV-2 infection
Access to the anonymised clinical data of the ISARIC-4C study for research purposes
Internally fundedApproved05/08/202025/08/2020
Addenbrooks HospitalEdward Banham-Hall
Risk of death among young Caucasian patients to inform whether a controlled human infection model with COVID-19 can be safely conducted - part of due dilligence
Patients between 20-29 who died of COVID-19. Demographic data - 23 from ISARIC report
Funding pending - Wellcome Trust
CAPACITY Trial/University of Glasgow ICAMS
Rhian Touyz, Colin Berry, Tuuli Hietamies, Katriona Brooksbank
Transfer of ISARIC4C data into the CAPACITY database
ISARIC dataset
BHF Core and CSO grants
Declined, study leads to engage
A Beclere-Saclay University Hospital
Roberta Raschetti
Systematic review on neonatal COVID-19 cases
Access to data by Swann et al. Data points: gestational age, birth weight, sex, c-section, 5min APGAR, comorbidities, DOL type of infection (congenital, intrapartum, postpartum)
Internally fundedApproved29/08/202018/12/2020
University of East LondonSamir Shawgy Ayoub
Anti-inflammatory mediator profiles in patients with mild and severe infections to elucidate anti-inflammatory pathways
5ml blood from COVID-19 patients with severe and mild symptoms
Funding pending
Declined, samples do not exist
Methods AnalyticsSimon Swift
Formal assesment of the impact of Remdesivir treatment in COVID-19
Individual level data on persons with a diagnosis of Covid19 and a flag indicating whether they had treatment with Remdesivir or not, and if so dosage data
Have informal approval of funding depending on data being available
COVID-NURSE Clinical Trial (University of Exeter)
David A Richards
Select Trusts with sufficient patient throughput for inclusion in the Covid Nurse trial
Number of patients currently admitted and treated for COVID-19 symptoms in UK NHS Trusts
NIHR/UKRI/MRC; Study Grant Ref: MR/V02776X/1
Study leads to engage20/09/202018/12/2020
National Center for Biotechnology, Madrid -Spain
Juan Manuel Luque
COVID19PATGENOME Bioinformatic analysis of genomic data from sequencing of COVID-19 patients that explains severity of this disease and to optimise treatment
Genomic data (FASTQ RNA/DNA files) from COVID-19 patients and their respective clinical data.
Grant funding requested/outstanding
Department of Cardiology, Renmin Hospital of Wuhan University
Ze Chen
Test the performance of our CBC score on ISARIC 4C dataset to assess its generalisability to other cohorts, and vice versa, to test and compare ISARIC 4C Score as applied to our Hubei cohort.
Data on 35,463 patients included in the derivation dataset of 4C Score
Grants from Chinese funding bodies
Medical Schooll of Athens
Eleni Karakike
Systematic review and meta-analysis of the incidence of (viral) sepsis (as defined by sepsis-3 criteria), associated with COVID-19. As part of a sepsis awareness initiative in COVID-19. Relevant protocol and design on PROSPERO database (CRD42020202018).
The following data are requested (prioritising the first bullet):
Number of patients with Sequential Organ Failure Assessment (SOFA) score
≥2, consequent to COVID-19 infection
Number of patients with Acute Respiratory Distress Syndrome (ARDS)
Number of patients with Acute Kidney Injury
Number of patients with Acute Kidney Injury
Number of patients requiring vasopressors
Number of patients presenting coagulopathy or Disseminated Intravascular
Coagulation (DIC)
Number of patients with lactate levels >2 mmol/l
Number of patients with mental alterations
Number of patients with bilirubin levels ≥ 1.2 mg/dl or Acute Liver Dysfunction
Number of patients with SOFA score ≥2 who die within the hospital, and number of patients with SOFA score <2 who die within the hospital.
No funding is required for this work.
UCL London Hospitals NHS Foundation Trust
Jessica Manson and Professor Liz Jury
Characterising the pathology underlying COV-HI for stratification of trials with immunomodulatory therapies, and potentially highlight novel therapeutic options
• Serum: 25 patients per group; 500ul serum sample from each at each time point: admission (baseline) and follow-up if available
• Whole blood RNA sequencing data: from 25 patients in Cohort A vs 25 patients in Cohort B.
• If RNA-seq data not available: whole blood RNA from 20 patients per group at Baseline (admission) and follow-up if available
• Accompanying clinical characterisation and laboratory data associated with the samples provided.
Applying to UKRIFor collaboration28/09/2020
5/11/20 (SAMPLE)